LQ-004

N/A

Report date: 2023/02/28 10:38:10

Base Information

Drug NameLQ-004
Drug Alias NameLQ-004LQ004
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Programmed death-ligand 1
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsSquamous Cell Carcinoma of Head and Neck
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Novamab Biopharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Novamab Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsSquamous Cell Carcinoma of Head and Neck
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A